CAS 384859-58-9

2-((3-(Ethoxycarbonyl)-6-(trifluoromethoxy)quinolin-4-yl)amino)benzoic acid

CAS : 384859-58-9

Formule : C₂₀H₁₅F₃N₂O₅

Degré de pureté : 98%

Masse moléculaire : 420.3387

Ref: IN-DA01KKVB

BCH001

CAS : 384859-58-9

BCH001

Degré de pureté : ≥98%

Masse moléculaire : 420.34g/mol

Ref: 54-BUP06668

2-((3-(Ethoxycarbonyl)-6-(Trifluoromethoxy)Quinolin-4-Yl)Amino)Benzoic Acid

CAS : 384859-58-9

2-((3-(Ethoxycarbonyl)-6-(Trifluoromethoxy)Quinolin-4-Yl)Amino)Benzoic Acid

Degré de pureté : 98%

Masse moléculaire : 420.34g/mol

Ref: 54-PC108479

BCH001

CAS : 384859-58-9

BCH001 is a specific small-molecule inhibitor of PAPD5.

Formule : C₂₀H₁₅F₃N₂O₅

Degré de pureté : 99.06%

Couleur et forme : Solid

Masse moléculaire : 420.34

Ref: TM-T8647

BCH001

CAS : 384859-58-9

BCH001 is a cell-based therapy that is indicated for use in neonates with congenital heart disease. It can be used to treat pulmonary fibrosis. BCH001 is an autologous bone marrow mononuclear cell product that contains telomerase, which has the ability to stabilize and maintain telomere length. The cells are injected into the patient’s blood stream and travel through the body. BCH001 cells have been shown to be able to differentiate into various types of cells such as cardiomyocytes and endothelial cells, depending on its environment. BCH001 also has the ability to stimulate production of pluripotent stem cells by activating genes that control pluripotency markers, making it a potential treatment for congenital diseases in children.

Formule : C₂₀H₁₅F₃N₂O₅

Degré de pureté : Min. 95%

Masse moléculaire : 420.3 g/mol

Ref: 3D-JQA85958